Cargando…

Exercise as Potential Therapeutic Target to Modulate Alzheimer’s Disease Pathology in APOE ε4 Carriers: A Systematic Review

Alzheimer’s disease (AD) is a progressive neurodegenerative disease for which no effective treatment exists at present. Previous research has found that exercise reduces the risk of AD. Since the apolipoprotein E (APOE) ε4 allele increases the risk of AD and is associated with faster disease progres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tokgöz, Sevilay, Claassen, Jurgen A. H. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126521/ https://www.ncbi.nlm.nih.gov/pubmed/33403644 http://dx.doi.org/10.1007/s40119-020-00209-z

Ejemplares similares

Bioenergetic and inflammatory systemic phenotypes in Alzheimer’s disease APOE ε4‐carriers
por: Wilkins, Heather M., et al.
Publicado: (2021)

A Systems View of the Differences between APOE ε4 Carriers and Non-carriers in Alzheimer’s Disease
por: Jiang, Shan, et al.
Publicado: (2016)

APOE-ε4 Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer Disease
por: Hou, Min, et al.
Publicado: (2021)

Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers
por: Sun, Yu, et al.
Publicado: (2019)

Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice
por: Pankiewicz, Joanna E, et al.
Publicado: (2014)

Identification of epigenome-wide DNA methylation differences between carriers of APOE ε4 and APOE ε2 alleles
por: Walker, Rosie M., et al.
Publicado: (2021)

Platelet cytochrome oxidase and citrate synthase activities in APOE ε4 carrier and non-carrier Alzheimer's disease patients
por: Wilkins, Heather M., et al.
Publicado: (2017)

Sex and APOE: A memory advantage in male APOE ε4 carriers in midlife
por: Zokaei, Nahid, et al.
Publicado: (2017)

Alterations in dorsal and ventral posterior cingulate connectivity in APOE ε4 carriers at risk of Alzheimer's disease
por: Kerestes, Rebecca, et al.
Publicado: (2015)

CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
por: Ahmad, Shahzad, et al.
Publicado: (2020)

A brain proteomic signature of incipient Alzheimer’s disease in young APOE ε4 carriers identifies novel drug targets
por: Roberts, Jackson A., et al.
Publicado: (2021)

Learning deficit in cognitively normal APOE ε4 carriers with LOW β‐amyloid
por: Lim, Yen Ying, et al.
Publicado: (2021)

The MAPT H1 Haplotype Is a Risk Factor for Alzheimer’s Disease in APOE ε4 Non-carriers
por: Sánchez-Juan, Pascual, et al.
Publicado: (2019)

Novel Alzheimer’s disease risk variants identified based on whole-genome sequencing of APOE ε4 carriers
por: Park, Jong-Ho, et al.
Publicado: (2021)

Short leukocyte telomeres predict 25-year Alzheimer's disease incidence in non-APOE ε4-carriers
por: Hackenhaar, Fernanda Schäfer, et al.
Publicado: (2021)

Midlife Lifestyle Activities Moderate APOE ε4 Effect on in vivo Alzheimer’s Disease Pathologies
por: Jeon, So Yeon, et al.
Publicado: (2020)

APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology
por: Talyansky, Seth, et al.
Publicado: (2023)

APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology
por: Talyansky, Seth, et al.
Publicado: (2023)

APOEε4 potentiates the relationship between amyloid-β and tau pathologies
por: Therriault, Joseph, et al.
Publicado: (2020)

Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers
por: Spotorno, Nicola, et al.
Publicado: (2022)

Differences in resting-state brain networks and gray matter between APOE ε2 and APOE ε4 carriers in non-dementia elderly
por: Wang, Zhiyuan, et al.
Publicado: (2023)

The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers
por: Benitez, Bruno A., et al.
Publicado: (2013)

Higher Level of Mismatch in APOE ε4 Carriers for Amyloid-Beta Peptide Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid
por: Vogelgsang, Jonathan, et al.
Publicado: (2019)

APOE ε4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer’s disease
por: Kim, Hongwon, et al.
Publicado: (2022)

Association of APOE Serum Levels and APOE ε2, ε3, and ε4 Alleles with Optic Neuritis
por: Momkute, Liucija, et al.
Publicado: (2022)

A loss of function variant in CASP7 protects against Alzheimer’s disease in homozygous APOE ε4 allele carriers
por: Ayers, Kristin L., et al.
Publicado: (2016)

Astrocytic expression of the Alzheimer’s disease risk allele, ApoEε4, potentiates neuronal tau pathology in multiple preclinical models
por: Jablonski, Angela Marie, et al.
Publicado: (2021)

Decreased plasma C‐reactive protein levels in APOE ε4 allele carriers
por: Martiskainen, Henna, et al.
Publicado: (2018)

Short-term memory advantage for brief durations in human APOE ε4 carriers
por: Zokaei, Nahid, et al.
Publicado: (2020)

Superior short-term memory in APOE ε2 carriers across the age range
por: Zokaei, Nahid, et al.
Publicado: (2021)

Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score
por: Ebenau, Jarith L., et al.
Publicado: (2021)

The Effects of rs405509 on APOEε4 Non-carriers in Non-demented Aging
por: Wu, Dongpeng, et al.
Publicado: (2021)

Differential association of cerebral blood flow and anisocytosis in APOE ε4 carriers at midlife
por: Dounavi, Maria-Eleni, et al.
Publicado: (2023)

APOE ε4, an Alzheimer’s disease susceptibility allele, and smoking cessation
por: Ashare, Rebecca L., et al.
Publicado: (2012)

Age‐dependent effects of APOE ε4 in preclinical Alzheimer's disease
por: Bonham, Luke W., et al.
Publicado: (2016)

APOEε4 and risk of Alzheimer’s disease – time to move forward
por: Lefterov, Iliya, et al.
Publicado: (2023)

The APOE ε4 Allele Affects Cognitive Functions Differently in Carriers of APP Mutations Compared to Carriers of PSEN1 Mutations in Autosomal-Dominant Alzheimer’s Disease
por: Almkvist, Ove, et al.
Publicado: (2021)

Patients with Alzheimer's disease who carry the APOE ε4 allele benefit more from physical exercise
por: Jensen, Camilla Steen, et al.
Publicado: (2019)

APOE ε2 is associated with increased tau pathology in primary tauopathy
por: Zhao, Na, et al.
Publicado: (2018)

Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
por: Zhang, Lan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_54le8a3p7a907t3k46go79fa1l